Literature DB >> 28541497

Improved Survival with Decreased Wait Time to Surgery in Glioblastoma Patients Presenting with Seizure.

Patrick M Flanigan1, Arman Jahangiri2, Ruby Kuang2, Albert Truong2, Sarah Choi2, Alvin Chou2, Jonathan W Rick2, Susan M Chang3, Annette M Molinaro4, Michael W McDermott2, Mitchel S Berger2, Manish K Aghi2.   

Abstract

BACKGROUND: Preoperative seizure is reported to confer favorable prognosis in glioblastoma patients, but studies to date have not investigated how broadly applicable seizure is as a prognostic factor.
OBJECTIVE: To investigate if prompter surgical intervention affects the relationship between preoperative seizure and prognosis in glioblastoma patients, focusing on the development of tumor growth and/or additional preoperative symptoms after seizure.
METHODS: Retrospective analysis of 443 patients (mean age = 60.2; 60% male) undergoing first glioblastoma resection at our institution (2005-2011).
RESULTS: Preoperative seizure(s) occurred in 28% of patients (n = 124), of which 63 (51%) had only seizure at presentation. Patients experiencing seizure as their only preoperative symptom ("seizure-only"; n = 45) survived over twice as long as patients who presented with seizure and then later developed additional preoperative symptoms (n = 18; "other symptoms postseizure"; 26.8 vs 10.2 months, P < .001) and patients without preoperative seizure ("no seizure"; 26.8 vs 13.1 months, P < .001). Multivariate stepwise analysis revealed preoperative seizures only (hazard ratio 0.54 [0.37-0.75]; P < .001) to be independently associated with increased survival. Longer wait time from presentation (ie, diagnostic magnetic resonance imaging) to surgery was a risk factor for developing additional symptoms. Eleven "other symptoms postseizure" patients (69%) vs 6 of the "seizure-only" patients (15%) had wait times >45 days (P < .001).
CONCLUSION: Seizure as the only preoperative symptom independently improved survival, however, when patients developed additional preoperative symptoms, typically due to surgical delay, no prognostic benefit was observed. Prompt diagnosis and neurosurgical intervention is warranted in patients with seizures without other preoperative symptoms to preserve their favorable prognosis. © Congress of Neurological Surgeons 2017.

Entities:  

Keywords:  Elderly; Glioblastoma; Oncology; Prognostic factors; Seizure

Mesh：

Year:  2017        PMID： 28541497      PMCID： PMC6257017          DOI： 10.1093/neuros/nyx084

Source DB:  PubMed          Journal:  Neurosurgery        ISSN： 0148-396X            Impact factor:   4.654


  20 in total

Review 1.  Glioblastoma survival: has it improved? Evidence from population-based studies.

Authors:  Adelheid Woehrer; Luc Bauchet; Jill S Barnholtz-Sloan
Journal:  Curr Opin Neurol       Date:  2014-12       Impact factor: 5.710

2.  Prognostic significance of seizure in patients with glioblastoma multiforme.

Authors:  N Ozbek; S Cakir; B Gursel; D Meydan
Journal:  Neurol India       Date:  2004-03       Impact factor: 2.117

Review 3.  Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatment.

Authors:  Jordi Bruna; Júlia Miró; Roser Velasco
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

4.  Prognostic implications of epilepsy in glioblastomas.

Authors:  Manuel Toledo; Silvana Sarria-Estrada; Manuel Quintana; Xavier Maldonado; Francisco Martinez-Ricarte; Jordi Rodon; Cristina Auger; Javier Salas-Puig; Estevo Santamarina; Elena Martinez-Saez
Journal:  Clin Neurol Neurosurg       Date:  2015-10-22       Impact factor: 1.876

5.  Glutamate is associated with a higher risk of seizures in patients with gliomas.

Authors:  Tanya I Yuen; Andrew P Morokoff; Andrew Bjorksten; Giovanna D'Abaco; Lucy Paradiso; Sue Finch; Daniel Wong; Christopher A Reid; Kim L Powell; Kate J Drummond; Mark A Rosenthal; Andrew H Kaye; Terence J O'Brien
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

6.  Prevalence and prognostic significance of epilepsy in patients with gliomas.

Authors:  K Lote; A E Stenwig; K Skullerud; H Hirschberg
Journal:  Eur J Cancer       Date:  1998-01       Impact factor: 9.162

7.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

8.  Seizure characteristics and control following resection in 332 patients with low-grade gliomas.

Authors:  Edward F Chang; Matthew B Potts; G Evren Keles; Kathleen R Lamborn; Susan M Chang; Nicholas M Barbaro; Mitchel S Berger
Journal:  J Neurosurg       Date:  2008-02       Impact factor: 5.115

9.  Glioblastoma cells induce differential glutamatergic gene expressions in human tumor-associated microglia/macrophages and monocyte-derived macrophages.

Authors:  Judy Choi; Beate Stradmann-Bellinghausen; Eduard Yakubov; Nicolai E Savaskan; Anne Régnier-Vigouroux
Journal:  Cancer Biol Ther       Date:  2015-06-05       Impact factor: 4.742

Review 10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Adam L Cohen; Sheri L Holmen; Howard Colman
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 6.030
View more
  8 in total

1.  Impact of seizures and antiseizure medication on survival in patients with glioma.

Authors:  Thinisha Sathis Kumar; Wan Muhammad Afnan; Chet-Ying Chan; Christine Audrey; Si-Lei Fong; Retnagowri Rajandram; Kheng-Seang Lim; Vairavan Narayanan
Journal:  J Neurooncol       Date:  2022-08-29       Impact factor: 4.506

Review 2.  Genetic secrets of long-term glioblastoma survivors.

Authors:  Ivana Jovčevska
Journal:  Bosn J Basic Med Sci       Date:  2019-05-20       Impact factor: 3.759

3.  Impact of a pandemic on surgical neuro-oncology-maintaining functionality in the early phase of crisis.

Authors:  N U Farrukh Hameed; Yixin Ma; Zili Zhen; Shuai Wu; Rui Feng; Weiping Li; Guodong Huang; Jinsong Wu; Zhongping Chen
Journal:  BMC Surg       Date:  2021-01-18       Impact factor: 2.102

4.  Preoperative and early postoperative seizures in patients with glioblastoma-two sides of the same coin?

Authors:  Yahya Ahmadipour; Laurèl Rauschenbach; Alejandro Santos; Marvin Darkwah Oppong; Lazaros Lazaridis; Carlos M Quesada; Andreas Junker; Daniela Pierscianek; Philipp Dammann; Karsten H Wrede; Björn Scheffler; Martin Glas; Martin Stuschke; Ulrich Sure; Ramazan Jabbarli
Journal:  Neurooncol Adv       Date:  2020-11-18

5.  A multidisciplinary neuro-oncological triage panel reduces the time to referral and treatment for patients with a brain tumor.

Authors:  Merijn E de Swart; Mathilde C M Kouwenhoven; Tessa Hellingman; Babette I Kuiper; Cathelijne Gorter de Vries; Machteld Leembruggen-Vellinga; Niels K Maliepaard; Ernest J Wouda; Bastiaan Moraal; David P Noske; Tjeerd J Postma; Esther Sanchez Aliaga; Bernard M J Uitdehaag; William P Vandertop; Barbara M Zonderhuis; Geert Kazemier; Philip C de Witt Hamer; Maaike Schuur
Journal:  Neurooncol Pract       Date:  2021-07-06

6.  The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial.

Authors:  Maoyuan Sun; Ning Huang; Yihao Tao; Rong Wen; Guanjian Zhao; Xiang Zhang; Zongyi Xie; Yuan Cheng; Jinning Mao; Guodong Liu
Journal:  Trials       Date:  2022-03-28       Impact factor: 2.279

7.  Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study.

Authors:  Domenique M J Müller; Merijn E De Swart; Hilko Ardon; Frederik Barkhof; Lorenzo Bello; Mitchel S Berger; Wim Bouwknegt; Wimar A Van den Brink; Marco Conti Nibali; Roelant S Eijgelaar; Julia Furtner; Seunggu J Han; Shawn Hervey-Jumper; Albert J S Idema; Barbara Kiesel; Alfred Kloet; Emmanuel Mandonnet; Pierre A J T Robe; Marco Rossi; Tommaso Sciortino; W Peter Vandertop; Martin Visser; Michiel Wagemakers; Georg Widhalm; Marnix G Witte; Philip C De Witt Hamer
Journal:  Neurooncol Adv       Date:  2021-04-08

8.  Prognostic Factors in Glioblastoma: Is There a Role for Epilepsy?

Authors:  Mauro Dobran; Davide Nasi; Stefano Chiriatti; Maurizio Gladi; Lucia di Somma; Maurizio Iacoangeli; Massimo Scerrati
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-01-16       Impact factor: 1.742
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.